Astellas Pharma Files Application for Candin Antifungal Agent Micafungin in EU.Tokyo, Japan, Apr 14, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 announced on April 13 that its European subsidiary has filed a Marketing Authorization Application (MAA MAA abbr. macroaggregated albumin ) for Astellas' proprietary candin antifungal agent, micafungin, with the European Medicines Agency The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. Until 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products. Roughly parallel to the U.S. . Astellas Pharma expects that micafungin will be applicable for the treatment of systemic fungal infections. Currently, micafungin is available in Japan and the US, under the trade names Funguard for Infusion and Mycamine, respectively. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion